BIO returns in-person with biotechs, Big Pharmas looking to make real life connections to survive bear market, @maxonwifi reports from San Diego #BIO2022
https://t.co/fkGRbVnsBD
Check out our exclusive interview with FDA oncology chief Richard Pazdur: “People want to take risks in oncology. I’ve been through this with family members and friends; it’s like ‘Doc, give it to me.’” #acceleratedapproval#oncology
https://t.co/PQVaIIkyGd
One of my favorite parts of @FiercePharma's drug name Madness is the "sounds like" critiques from our readers. Airport wifi, fire-breathing dragon, Megan Thee Stallion duet partner ... and more.
Even if your pick doesn't win #FierceMadness, we're sharing our favorite comments from voters here in our Fierce Hall of Fame. Check out the comments below, and ICYMI here's our running coverage of this year's challenge. https://t.co/BICTyXSxyz
Last day to vote in this round of @FiercePharma's 2022 #FierceMadness drug name tournament! Check out the bracket below and then vote here: https://t.co/LCNYReHdvu
Really proud of the biotech, healthcare and pharma editorial teams here at Fierce. We have a raft of finalist nods in the Neal awards, plus more in the Azbees. Check out both threads below for the stories and news coverage that rated.
But that's not all! Fierce Biotech has also been named as a finalist for 2 Jesse H. Neal Awards, including Best Media Brand in the Overall Editorial Excellence category! https://t.co/An1s7MMT4N
Fierce Biotech has been named as a finalist for 3 regional and 2 national Azbee Awards of Excellence! See our award-winning coverage below
https://t.co/fDgSR0BnFt
It’s deja vu all over again. These are the questions that the FDA Advisory Committee unanimously decided more than a year ago had not been answered for aducanumab. The FDA’s accelerated approval has been a pointless disaster for people with Alzheimer’s and our Field.
$ABBV is down 10% after the FDA said makers of JAK inhibitors must add warnings of heart conditions, blood clots, cancer and death to their labels. This also impacts $PFE and $LLY. This doesn't pertain to drugs from $INCY and $BMY, however.
New rule....investors start preferring public AdComs. No more cheering when a drug doesn't get one. It's the strongest part of the regulatory process that brings out truth. Keeps companies honest.
My 5 "perfect storm" worries for Texas:
1. "No vaccines" we still haven't picked up the pace post Ice Harvey, ranking near bottom for vaccinations.
2. No masks
3. Rising B..1.1.7 variant based on new Houston Health wastewater data.
4. Slight rise in positivity
5. Spring Break
@RebZam@ohheyjenna Our newsroom is expanding. Scouting for a half-dozen smart journalists who'd like to make a difference covering the science and business of the pandemic. Medtech, biotech, pharma, healthcare. #journojobs posts link below, or DM me. https://t.co/pZxDDqbmO7
Lots of Moderna news yesterday/today: booster shot study, new production targets, CMO exit and $18 billion in expected COVID vaccine sales this year. Up from about $11 billion they projected just last month.
https://t.co/Dmu4MATB4N
Scouting for smart journalists who'd like to make a difference covering the science and business of the pandemic. Medtech, biotech, pharma—we're an ambitious and growing team. #journojobs posts link below, or DM me: https://t.co/z0Ak0DOIgW
Yikes! The number of clinical trials for #oncology#drugs dropped by 60% during #COVID19 pandemic period @Medidata@JAMANetworkOpen
https://t.co/laGzvXcf3g
Fewer new therapies will be launched in coming years. That's the wrong way to curb drug spending.
The White House has resumed the search for a permanent FDA commissioner in the face of opposition from D senators to Janet Woodcock. A final decision has not been made, but Woodcock's chances are slipping. Josh Sharfstein, is no longer being considered. https://t.co/dgEK5zDV2F